{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:03:12Z","timestamp":1778648592198,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Veterinary Cardiology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jvc.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T15:37:44Z","timestamp":1534520264000},"page":"376-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs"],"prefix":"10.1016","volume":"20","author":[{"given":"M.","family":"Konta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-9006","authenticated-orcid":false,"given":"M.","family":"Nagakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvc.2018.07.009_bib1","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jvc.2018.07.009_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2004.005","article-title":"Aldosterone and cardiovascular remodelling: focus on myocardial failure","volume":"5","author":"Shieh","year":"2004","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jvc.2018.07.009_bib3","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.jvc.2018.07.009_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","author":"BENCH (BENazepril in Canine Heart disease) Study Group","year":"1999","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2018.07.009_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jvc.2017.06.001","article-title":"Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone- a pilot study","volume":"19","author":"Hezzell","year":"2017","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jvc.2018.07.009_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320316633897","article-title":"Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition","volume":"17","author":"Ames","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jvc.2018.07.009_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","article-title":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","volume":"19","author":"Ames","year":"2017","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib10","first-page":"3","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"9","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jvc.2018.07.009_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jvp.12154","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Therapeut"},{"key":"10.1016\/j.jvc.2018.07.009_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jvp.12216","article-title":"The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Therapeut"},{"key":"10.1016\/j.jvc.2018.07.009_bib13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","article-title":"The effect of high dose enalapril and benazepril on the pharmacologically-activated renin-angiotensin-aldosterone system in the normal dog","volume":"76","author":"Ames","year":"2015","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2018.07.009_bib14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jvim.12471","article-title":"Telmisartan treatment of refractory proteinuria in a dog","volume":"28","author":"Bugbee","year":"2014","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2018.07.009_bib15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/jvim.13639","article-title":"Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kindey disease","volume":"29","author":"Sent","year":"2015","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2018.07.009_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1939-1676.2007.tb03005.x","article-title":"Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"21","author":"Brown","year":"2007","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2018.07.009_bib17","series-title":"Textbook of Veterinary Internal Medicine","first-page":"671","article-title":"Systemic hypotention","author":"Waddell","year":"2017"},{"key":"10.1016\/j.jvc.2018.07.009_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jvc.2018.07.009_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jvc.2018.07.009_bib20","series-title":"Plumb's veterinary drug handbook","first-page":"1001","author":"Plumb","year":"2015"},{"key":"10.1016\/j.jvc.2018.07.009_bib21","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jvc.2018.07.009_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.jvc.2018.07.009_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9149(90)90952-W","article-title":"Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension","volume":"65","author":"Weber","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib25","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2018.07.009_bib26","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2460\/ajvr.73.11.1765","article-title":"Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease","volume":"73","author":"Hezzell","year":"2012","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2018.07.009_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jvc.2014.08.002","article-title":"Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease","volume":"16","author":"Hezzell","year":"2014","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2018.07.009_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2018.07.009_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jce.12115","article-title":"Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation","volume":"24","author":"Esposito","year":"2013","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Journal of Veterinary Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273417302023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273417302023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:52:02Z","timestamp":1720518722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1760273417302023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1760273417302023"],"URL":"https:\/\/doi.org\/10.1016\/j.jvc.2018.07.009","relation":{},"ISSN":["1760-2734"],"issn-type":[{"value":"1760-2734","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs","name":"articletitle","label":"Article Title"},{"value":"Journal of Veterinary Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvc.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}